In a randomized trial of men with a single suspicious lesion on MRI, targeted perilesional biopsy matched standard targeted and systematic biopsy for detecting clinically significant prostate cancer - ...

New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate-specific antigen relapse.

A new study found that a DNA sequencing test for advanced prostate cancer patients can distinguish between patients with poor and favorable prognoses. Published in Nature Communications, a new study ...

A novel long-term prediction model showed promise at estimating the risk for dying of prostate cancer, an analysis published in Annals of Internal Medicine indicated.“We have developed a tool that can ...

Doctors began testing PSA levels in the 1980s to monitor diagnosed cancers. By the early 1990s, researchers promoted it for ...

Prostate cancer is the second-leading cause of cancer death in American men.About 1 in 8 men will be diagnosed with prostate ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

The MarketWatch News Department was not involved in the creation of this content. GRENOBLE, France and PRINCETON, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS ("Koelis" or the "Company", ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

In a biopsy, a small sample of tissue is taken from your body. A pathologist analyzes the sample to check for cancer cells. The main method for diagnosing prostate cancer is a core needle biopsy. It’s ...

MONDAY, Dec. 30, 2024 (HealthDay News) -- Men with negative multiparametric magnetic resonance imaging (mpMRI) results avoiding biopsy do not have an increased risk for clinically significant prostate ...